The metastatic phenotype - Prognostic implications

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 2, 1996, Pages 71-96

  Lindblom, Annika ^a   Linder, Stig ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DISSEMINATED CANCER; GENE EXPRESSION; HUMAN; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROGNOSIS; REVIEW;

EID: 0030271098     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00213-2     Document Type: Review

References (322)

1. [1] Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:5054s-5059s, 1991.
2. [2] Nicolson GL. Cancer progression and growth: Relationship of paracrine and autocrine growth mechanisms to organ preference and metastasis. Exp Cell Res 204:171-180, 1993.
3. [3] Mareel MM, Van Roy FM, De Baetselier P. The invasive phenotypes. Cancer Metastasis Rev 9:45-62, 1990.
4. [4] Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 10:115-128, 1991.
5. [5] Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991.
6. [6] Rusciano D, Burger MM. Why do cancer cells metastasize into particular organs? Bioessays 14:185-194, 1992.
7. [7] Steeg PS. Invasion and metastasis. Curr Opin Oncol 4:134-141, 1992.
8. [8] Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573, 1993.
9. [9] Liotta LA, Stetler-Stevenson WG. Principles of molecular cell biology of cancer: cancer metastasis. Cancer Principles Practice Oncol 4:134-146, 1993.
10. [10] Weinstein IB. The origins of human cancer: molecular mechanisms of carcinogenesis. Cancer Res 48:4135, 1988.
11. [11] Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322:78-80, 1986.
12. [12] Kumar R, Sukumar S, Barbacid M. Activation of ras oncogenes preceding the onset of neoplasia. Science 248:1101-1104, 1990.
13. [13] Yuspa SH, Kilkenny A, Cheng C, Roop D, Hennings H, Kruszewski F, Lee E et al. Alterations in epidermal biochemistry as a consequence of stage-specific genetic changes in skin carcinogenesis. Environ Health Perspect 93:3-10, 1991.
14. [14] Devary Y, Gottlieb RA, Smeal T, Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71:1081-1091, 1992.
15. [15] Sachsenmaier C, Radler-Pohl A, Zinek R, Nordheim A, Herrlich P, Rahmsdorf HJ. Involvement of growth factor receptors in the mammalian UV response. Cell 94:963-972, 1994.
16. [16] Nowell PC. Cytogenetics of tumor progression. Cancer 65:2172-2177, 1990.
17. [17] Foulds L. Neoplastic Development. New York: Academic Press, 1975.
18. [18] Nowell PC. The clonal evolution of tumor cell populations. Science (Wash. DC) 194:23-28, 1976.
19. [19] Clark WC. Tumour progression and the nature of cancer. Br J Cancer 64:631-644, 1991.
20. [20] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
21. [21] Gingras MC, Jarolim L, Finch J, Bowden GT, Wright JA, Greenberg AH. Transient alterations in the expression of protease and extracellular matrix genes during metastatic lung colonization by H-ras-transformed 10T1/2 fibroblasts. Cancer Res 30:4061-4066, 1990.
22. [22] Nicolson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47:1473-1487, 1987.
23. [23] Poste G, Fidler IJ. Nature 283:139-146, 1980.
24. [24] Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 242:148-149, 1973.
25. [25] Weiss L. Metastatic inefficiency. Adv Cancer Res 54:159-211, 1990.
26. [26] Morris VL, MacDonald ICSK, Schmidt EE, Chambers A, Groom AC. Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin. Exp. Metastasis 11:377-390, 1993.
27. [27] Fidler IJ. Metastasis as a consequence of abberant homeostasis. Clin Exp Metastasis 10:5-7, 1992.
28. [28] Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 88:6028-6032, 1991.
29. [29] Kerbel R. Expression of multicytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Am J Pathol 141:519-524, 1992.
30. [30] Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55:87-132, 1990.
31. [31] Dear TN, Kefford RF. Molecular oncogenetics of metastasis. Molec Aspects Med 11:243-324, 1990.
32. [32] O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung Carcinoma. Cell 79:315-328, 1994.
33. [33] Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47:487-498, 1986.
34. [34] Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611-619, 1983.
35. [35] Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245, 1987.
36. [36] Schor SL, Schor AM, Winn B, Rushton G. The use of three-dimensional collagen gels for the study of tumor cell invasion in vitro: experimental parameters influencing cell migration into the gel matrix. Int J Cancer 29:57-62, 1982.
37. [37] Mareel M, Kint J, Meyvisch C. Methods of study of the invasion of malignant C3H mouse fibroblasts into embryonic chick heart in vitro. Virchows Arch 30:95-111, 1979.
38. [38] Sidebottom E, Clark SR. Cell fusion segregates progressive growth from metastasis. Br J Cancer 47:399-405, 1983.
39. [39] De Baetselier P, Roos E, Brys L, Remels L, Gobert M, Dekekel D, Segal S et al. Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells. Cancer Metastasis Rev 3:5-24, 1984.
40. [40] Collard JG, Roos E, La Riviere G, Habets GG. Genetic analysis of invasion and metastasis. Cancer Surv 7:691-710, 1988.
41. [41] Fournier REK, Ruddle FH. Microcell-mediated transfer of murine chromosomes into mouse, Chinese hamster and human somatic cells. Proc Natl Acad Sci USA 74:319-323, 1977.
42. [42] Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Stanbridge EJ, Weissman BE. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenesis. Oncogene 9:255-262, 1994.
43. [43] Jen J, Kim H, Piantadosi S, Liu Z-F, Levitt RC, Sistonen P, Kinzler KW et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. New Engl J Med 331:213-221, 1994.
44. [44] Bieche I, Champene MH, Matifas F, Hacene K, Callahan R, Liereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339:1990-1994, 1992.
45. [45] Lindblom A, Rotstein S, Skoog L, Nordenskjöld M, Larsson C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res 53:3707-3711, 1993.
46. [46] Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989.
47. [47] Slamon DJ. Expression on the nm23 gene and breast cancer prognosis. JNCI 83, no. 4:229-231, 1991.
48. [48] Wang L, Patel U, Ghosh L, Chen H-C, Banerjee S. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res 53:717-720, 1993.
49. [49] Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ et al. Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
50. [50] Borg Å, Zhan Q-X, Olsson H, Wenngren E, Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastasis and poor prognosis respectively. Genes Chrom Cancer 3:311-320, 1993.
51. [51] Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal groxth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev 13:3-17, 1992.
52. [52] Rochefort H, Capony F, Garcia M. Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells 2:383-388, 1990.
53. [53] Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussman I, Matzku S et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24, 1991.
54. [54] Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971, 1992.
55. [55] Matrisian LM, Glaichenhaus N, Gesnel MC, Breatnach R. Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J 4:1435-1440, 1985.
56. [56] Barraclough R, Savin J, Dube SK, Rudland PS. Molecular cloning and sequence of the gene for p9Ka. A cultured myoepithelial cell protein with strong homology to S-100, a calcium-binding protein. J Mol Biol 198:13-20, 1987.
57. [57] Ebralidze A, Tulchinsky E, Grigorian M, Afanasyeva A, Senin V, Revazova E, Lukanidin E. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to Ca2+ binding protein family. Genes Dev 3:1086-1093, 1989.
58. [58] Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200-209, 1988.
59. [59] Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, Westin EH, Heilman CA, Talmadge JE. Liotta LA. NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice. Mol Cell Biol 5:259-262, 1985.
60. [60] Egan SE, Wright JA, Jarolim L, Yanigahara K, Bassim RH, Greenberg AH. Transformation by oncogenes encoding protein kinases induces the metastatic phenotype. Science 238:202-204, 1987.
61. [61] Smith MR, DeGudicibus SJ, Stacey DW. Requirement for c-ras proteins during viral oncogen transformation. Nature 320:540-543, 1986.
62. [62] Ruiz-Cabello F, Klein E, Garrido F. MHC antigens on human tumors -minireview. Immunol Lett 29:181-190, 1991.
63. [63] Leone A, Flatow U, King CR. Sandeen MA, Margulies IMK, Liotta LA, Steeg PS. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65:25-35, 1991.
64. [64] Davies BR, Davies M, Gibbs F, Barraclough R, Rudland PS. Induction of the metastatic phenotype by transfection of a benign rat epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 8:999-1008, 1993.
65. [65] Kerbel RS, Waghorne C, Man MS, Elliot B, Breitman ML. Alteration of the tumorigenic and metastastic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proc Natl Acad Sci USA 84:1263-1267, 1987.
66. [66] Castronovo V, Kusaka M, Chariot A, Gielen J. Sobel M. Homeobox genes: potential candidates for the transcriptional control of the transformed and invasive phenotype. Biochem Pharmacol 47:137-142, 1994.
67. [67] Nicolson GL, Gallick GE, Spohn WH, Lembo TM, Tainsky MA. Transfection of activated c-H-rasEJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification of spontaneous metastatic and cell-surface properties. Oncogene 7:1127-1135, 1992.
68. [68] Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfleiderer A, Wagner E. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes. Cancer 71:419-429, 1993.
69. [69] Volm M, van Kaick G. Mattern J. Analyses of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis 12:329, 1994.
70. [70] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
71. [71] Yokota J, Yamamoto T, Miyajima N, Toyoahima K, Nomura N, Sakamoto H, Yoshida T et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2:283, 1988.
72. [72] Broudeur GM, Seeger RC, Schwab M. Varmus HE, Bishop JM. Amplification of n-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984.
73. [73] Combaret V, Wang Q, Favrot MC, Thiesse P, Philip I, Bouffet E, Bailly C et al. Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Cancer and Clin Oncol 25:1607-1612, 1989.
74. [74] Bos JL, Fearon ER, Hamilton SR, Verlaan de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras oncogene mutations in human colorectal cancer cells. Nature 327:293-297, 1987.
75. [75] Albini AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt MS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype, Oncogene 4:1363-1374, 1989.
76. [76] Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res 5:121-127, 1989.
77. [77] Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.
78. [78] Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357-360, 1989.
79. [79] Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nature Med 1:309-320, 1995.
80. [80] Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncog 4:95-114, 1993.
81. [81] Binétruy B, Smeal T, Karin M. Ha-ras augments c-jun activity and stimulates phosphorylation of its activation domain. Nature 351:122-127, 1991.
82. [82] Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 9:2241-2246, 1990.
83. [83] Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 10:1127-1134, 1991.
84. [84] Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395-405, 1993.
85. [85] Lloyd A, Yancheva N, Wasylyk B. Transformation suppressor activity of a Jun transcription factor lacking its activation domain. Nature 352:635-638, 1991.
86. [86] Marshall-Heyman H, Engel G, Ljungdahl S, Shoshan MC, Svensson C, Wasylyk B, Linder S. Tumorigenic and metastatic properties of two T24-ras transformed rat fibroblast cell lines defective in c-jun. Oncogene 9:3655-3663, 1994.
87. [87] Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N. Moro D, Brambilla C et al. Expression of c-ets-1. collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 147:1298-1310, 1995.
88. [88] Weinberg RA. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res 49:3713-3722, 1989.
89. [89] Hanahan D. Transgenic mice as probes into complex systems. Science 246:1265-1275, 1989.
90. [90] Kriajevska MV, Cardenas MN, Grigorian MS, Ambartsumian NS, Georgiev GP, Lukanidin EM. Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 269:19679-19682, 1994.
91. [91] Ford HL, MM Salim, R Chakravarty, V Aluiddin, SB Zain. Expression of Mtsl, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene 11:2067-2075, 1995.
92. 2+ binding proteins of the S100 family in malignant human breast-cancer cell lines and biopsy samples. Int J Cancer 57:684-690, 1994.
93. [93] Sharp MGF, Adams SM, Elvin P, Walker RA, Brammar WJ, Varley JM. A sequence previously identified as metastasis related encodes an acidic ribosomal phosphoprotein, P2. Br J Cancer 61:83-88, 1990.
94. [94] Butler WT. The nature and significance of osteopontin. Connect Tissue Res 23:123-136, 1989.
95. [95] Behrend EI, Craig AM, Wilson SM, Denhart DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin mRNA. Cancer Res 54:832-837, 1994.
96. [96] Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 15:476-487, 1995.
97. [97] Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299, 1989.
98. [98] Habets GGM, Scholtes EHM, Zuydgeest D, van der Kammen R, Stam JC, Berns A, Collard JG. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77:537-549, 1994.
99. [99] Michiels F, GG Habets, JC Stam, RA van der Kammen, JG Collard. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375:338-340, 1995.
100. [100] Fearon E, Cho K, Nigro J, et al. Identification of a chromosome 18q gene that is altered in colorectal cancer. Science 247:49-56, 1990.
101. [101] Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y. Allelotype of breast cancer, cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50:7184-7189, 1990.
102. [102] Rosengard AM, Krutzsch HC, Shearn A, Biggs JR, Barker E, Margulies IMK, King CR et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 342:177-180, 1989.
103. [103] Liotta LA, Steeg PS. Clues to the function of Nm23 and Awd proteins in development, signal transduction, and tumor metastasis provided by studies of dictyostelium discoideum. J Natl Cancer Inst 82:1170-1172, 1990.
104. [104] MacDonald NJ, De la Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 31A:1096-1100, 1995.
105. [105] MacDonald NJ, De la Rosa A, Benedict MA, Freije JM. Krutsch H, Steeg PS. A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J Biol Chem 31:113-124, 1993.
106. [106] Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 8:2325-2333, 1993.
107. [107] Howlett AR, Petersen OW, Steeg PS, Bissell MJ. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 86:1838-1845, 1994.
108. [108] Nakamori S, Ishikawa O, Ohhigashi H, Kameyama M, Furukawa H, Sasaki Y, Inaji H et al. Expression of the nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin Exp Metastasis 11:151-158, 1993.
109. [109] Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, Reynolds CP et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 88:341-345, 1991.
110. [110] Haut M, Steeg PS, Willson JKV, Markowitz SD. Induction of nm23 gene expression in human clonic neoplasms and equal expression in colon tumors of high and low metastatic potential. J Natl Cancer Inst 83:712-715, 1991.
111. [111] Dear TN, Ramshaw LA, Kefford RF. Differential expression of a novel gene, WDNM1, in non metastatic rat mammary adenocarcinoma cells. Cancer Res 48:5203-5208, 1988.
112. [112] El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
113. [113] Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases. Nature 376:88-91, 1995.
114. [114] Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995.
115. [115] Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
116. [116] Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
117. [117] Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutants in p53 produce common conformation defects. A monoclonal antibody specific for the mutant form. EMBO J 9:1591-1602, 1990.
118. [118] Sun X-F, Carstensen JM, Zhang H, Stål O, Wingre S, Hatschek T, Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenomcarcinoma. Lancet 340:1369-1373, 1992.
119. [119] Fearon ER, B Vogelstein. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
120. [120] Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred C, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 26:225-235, 1993.
121. [121] Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RC. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65:40-44, 1992.
122. [122] Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128-2132. 1993.
123. [123] Shiao Y-H, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol 144:511-517, 1994.
124. [124] Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846-847, 1992.
125. [125] Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990.
126. [126] Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V. p53 increases experimental metastatic capacity of murine carcinoma cells. Mol Cell Biol 8:2078-2081, 1988.
127. [127] Ohta M, Inoue H, Cotticelli MG, Kasturi K, Baffa R, Palazzo J, Siprasvili Z et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597, 1996.
128. [128] Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997-1004, 1974.
129. [129] Takeichi M. Cadherins:A molecular family important in selective cell-cell adhesion. Annu Rev Biochem 59:237-252, 1990.
130. [130] Kusama T, Nakamori S, Ohigashi H, Mukai M, Shinkai K, Ishikawa O, Imaoka S et al. Enhancement of in vitro tumor-cell transcellular migration by tumor-cell-secreted endothelial-cell-retraction factor. Int J Cancer 63:112-118, 1995.
131. [131] Nicolson GL. Metastatic tumor cell interactions with endothelium, basement membrane and tissue. Curr Opin Cell Biol 1:1009-1019, 1989.
132. [132] Sindelar WF, Tralka TS, Ketcham AS. Electron microscopic observations on formation of pulmonary metastases. J Surg Res 18:137-167, 1975.
133. [133] Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9:391-405, 1989.
134. [134] Halaka AN, Bunning RAD, Bird CC. Gibson M, Reynolds JJ. Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg 59:461-466, 1983.
135. [135] Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chaing PK, Schifferman E. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83:3302-3306, 1986.
136. [136] Gasic GJ. Role of plasma, platelets and endothelial cells in tumor metastasis. Cancer Metastasis Rev 3:99-114, 1984.
137. [137] Ruoslahti E, Giancotti FG. Integrins and tumor cell dissemination. Cancer Cells 1:119-126, 1989.
138. [138] Nicolson GL, Poste G. Tumor implantation and invasion at metastatic sites. Int Rev Exp Pathol 25:77-181, 1983.
139. [139] Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1:571, 1889.
140. [140] Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion, and growth of malignant cells at specific secondary sites. Cancer Metastasis 7:143-188, 1988.
141. [141] Weiss L, Nannmark U, Johansson BR, Bagge U. Lethal deformation of cancer cells in the microcirculation: a potential rate regulator of hematogeneous metastasis. Int J Cancer 50:103-107, 1992.
142. 125I-5-iodo-2′-deoxyuridine. J. Natl Cancer Inst 45:773-782, 1970.
143. [143] Lichtner RB, Belloni PN, Nicolson GL. Differential adhesion of metastatic rat mammary cells to organ-derived microvessel endothelial cells and subendothelial matrix. Expl Cell Biol 57:146-152, 1989.
144. [144] Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived chemoattractants. Cancer Res 45:3517-3521, 1985.
145. [145] Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1:149-153, 1995.
146. [146a] Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl. J Med 315:1650-1659, 1986.
147. [146b] Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989.
148. [147] Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40:687-690, 1987.
149. [148] Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 76:777-779, 1994.
150. [149] Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86:1286-1296, 1994.
151. [150] Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M. Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60:54-60, 1995.
152. [151] Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 948:67-85, 1988.
153. [152] Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65, 1977.
154. [153] Folkman J, Shing Y. Angiogenesis. J Biol Chem 267:10931-10933, 1992.
155. [154] Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF. Vallee BL. Biochemistry 24:5480-5486, 1985.
156. [155] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995.
157. [156] Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994.
158. [157] Srivastava A, Laidler P, Hughes LE. Neovascularization in human cutaneous melanoma: A quantitative morphological and Doppler ultrasound study. Eur J Cancer Clin Oncol 1205-1209, 1986.
159. [158] Carnochan P, Briggs JC, Westbury G, Davies AJS. The vascularity of cutaneous melanom: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer 64:102-107, 1991.
160. [159] Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
161. [160] Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992.
162. [161] Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992.
163. [162] Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993.
164. [163] Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995.
165. [164] Hall NR, Fish DE, Hunt N, Goldin RD, Guillou PJ, Monson JRT. Is the relationship between angiogenesis and metstasis in breast cancer real? Surg Oncol 1:223-229, 1992.
166. [165] Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1993.
167. [166] Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-845, 1993.
168. [167] Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993.
169. [168] Ingber D, FujitaT, Kishimoto S, Sudok I, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990.
170. [169] Gasparini G, Harris AL. Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 30A:201-206, 1994.
171. [170] Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992.
172. [171] Integrins in cancer. Cancer Metastasis Rev 14: 1995.
173. [172] Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233:467-469, 1986.
174. [173] Albelda SM, Mette SA, Elder DE, Stewart RM, Damjanovich L et al. Integrin distribution in malignant melanoma: association of the β-3-subunit with tumor progression. Cancer Res 50:6757-6764. 1990.
175. [174] Zutter MM, Mazoujian G, Santoro SA. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137:863-870, 1990.
176. [175] Qian F, Vaux DL, Weissman IL. Expression of the integrin α4β1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77:335-347, 1994.
177. [176] Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994.
178. [177] Behrens J. The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 24:175-184, 1993.
179. [178] Mareel M. Bracke M, van Roy F, Vakaet L. Expression of E-cadherin in embryogenetic ingression and cancer invasion. Int. J Dev Biol 37:227-235, 1993.
180. [179] Vleminckx K, Vackat L, Mareel M, Fiers W, Van Roy FV. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107-119, 1991.
181. [180] Behrens J, Mareel MM, van Roy FM, Birchmeier W. Dissecting tumor cell invasion, epithelial cells accquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108:2435-2447. 1989.
182. [181] Pignatelli M, E-cadherin, a biological marker of tumour differentiation. J Pathol 171:81-82, 1993.
183. [182] Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer, biological significance and clinical implications. Cancer Metastasis Rev 12:29-37, 1993.
184. [183] Dorudi S, Sheffield JP, Poulsom R, Northover JMA, Hart IR. E-cadherin expression in colorectal cancer, an immunocytochemical and in situ hybridization study. Am J Patol 142:981-986, 1993.
185. [184] Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53:1696-1701, 1993.
186. [185] Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmaier W, Sugimura T et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 91:1858-1862, 1994.
187. [186] Becker K-F, Atkinson MJ. Reich U, Becker I, Nekarda H, Siewert JR, Höfler H. E-cadherin mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845-3852, 1994.
188. [187] MacCalman CD, Brodt P, Doublet JD, Jednak R, Elhilali MM, Bazinet M, Blaschuk OW. The loss of E-cadherin mRNA transcripts in rat prostatic tumors is accompanied by increased expression of mRNA transcripts encoding fibronectin and its receptor. Clin Exp Metastasis 12:101-107, 1994.
189. [188] Ozawa M, Ringwald M, Kemler R. Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci USA 87:4246-4250, 1990.
190. [189] Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S et al. Association of the APC gene product with β-catenin. Science 262:1731-1734, 1993.
191. [190] Su L-K, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 262:1734-1737, 1993.
192. [191] Stanford DR, Starkey JR, Magnuson JA. The role of tumor-cell surface carbohydrate in experimental metastasis. Int J Cancer 37:435-444, 1986.
193. [192] Lasky LA. Lectin cell adhesion molecules, a new family of cell adhesion proteins ivolved with inflammation. J Cell Biochem 45:139-146, 1991.
194. [193] Aruffo A, Dietsch M, Wan H, Hellström KEIH. Granule membrane protein 140 binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci USA 89:2292-2296, 1992.
195. [194] Meromsky L, Lotan R, Raz A. Implications of endogenous tumor cell surface lectins as mediators of cellular interactions and lung colonization. Cancer Res 46:5270-5275, 1986.
196. [195] Öbrink B. C-CAM a member of the growing immunogluobulin superfamily of cell adhesion proteins. Bioessays 13:227-234, 1991.
197. [196] Rucklidge GJ, Edvardsen K, Bock E. Cell-adhesion molecules and metalloproteinases: a linked role in tumour cell invasiveness. Proteases Cancer 22:63-68, 1994.
198. [197] Edelman GM, Crossin KL. Cell adhesion molecules, implications for a molecular histology. Annu Rev Biochem 60:155-190, 1991.
199. [198] Jessup JMPT. Carcinoembryonic antigen; function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev 8:263-280, 1989.
200. [199] Kaetzel MA, Dedman JR. Affinity-purified site-directed antibody recognizes the entire annexin protein family. Biochem Biophys Res Comm 160:1233-1237, 1989.
201. [200] Yeatman TJ, Updyke TV, Dedman JR, Nicolson GL. Expression of annexins on the surfaces of nonmetstatic and metastatic human and rodent tumor cells. Clin Exp Metastasis 1992.
202. [201] Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 267:4732-4739, 1992.
203. [202] Seiter S, Arch R, Reber S, Komitowski M, Hofmann M, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:3988-3992, 1993.
204. [203] Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340:1053-1058, 1992.
205. [204] Wielenga VJM, Heider K-H, Offerhaus JA, Adolf GR, van den Berg FM, Ponta H, Herrlich P et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53:4754-4756, 1993.
206. [205] Weiner TM, Kornberg L, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 55:2752-2755, 1995.
207. [206] Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJ. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 302:157-162, 1991.
208. [207] Nagase HOY, Suzuki K, Enghild JJ, Salveson G. Substrate specificies and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 19:715-718, 1991.
209. [208] Woessner JJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154, 1991.
210. [209] Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145-155, 1992.
211. [210] Brenner CA, Adler RR, Rappolee DA, Pedersen RA, Werb Z. Genes for extracellular matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed early during mammalian development. Genes Dev 3:848-859, 1989.
212. [211] Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 88:8154-8158, 1991.
213. [212] Bonfil RD, Reddel RR, Ura H, Reich R, Fridman R, Harris CC, Klein-Szanto JP. Invasive and metastatic potential of a v-Ha-ras transformed human bronchial epithelial cell line. J Natl Cancer Inst 81:587-594, 1989.
214. [213] Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive poteintal in severe combined immunodeficient mice. Cancer Res 53:417-422, 1993.
215. [214] Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloprotease genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 52:4942-4947, 1992.
216. [215] Engel G, Popowicz P, Marshall H, Norling G, Svensson C, Auer G, Akusjärvi G, Linder S. Elevated stromelysin-1 and reduced collagenase IV expression in invasive rat embryo fibroblasts expressing E1A deletion mutants + T24-H-ras. Int J Cancer 51:761-766, 1992.
217. [216] Dickson RB, Shi YE, Johnson MD. Matrix-degrading proteases in hormone-dependent breast cancer. Breast Cancer Res Treat 31:167-173, 1994.
218. [217] Nabeshima K, Lane WS, Biswas C. Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 285:90-96, 1991.
219. [218] Basset P, Bellocq JP, WoIf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704, 1990.
220. [219] Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Danø K, Tryggvason K. Localization of messenger RNA for Mr 72 000 and 92 000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 52:1336-1341, 1992.
221. [220] van der Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histiological differentiation in colorectal tumors. Int J Cancer 45:1071-1078, 1990.
222. [221] Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 49:666-672, 1991.
223. [222] Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66:1188-1194, 1992.
224. [223] Gray ST, Wilkins RJ, Yun K. Interstitial collagenase gene expression in oral squamous cell carcinoma. Am J Pathol 141:301-306, 1992.
225. [224] Muller D, Breathnach R, Engelmann A. Milton R, Bronner G, Flesch H, Dumont P et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 48:550-556, 1991.
226. [225] Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P. Detection of mRNAs encoding collagenase 1 and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 11:76-83, 1991.
227. [226] Clavel C, Polette M, Doco M, Binninger I, Birembaut P. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 79:261-270, 1992.
228. [227] Levy AT, Ciose V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetier-Stevenson WG. Increased expression of the Mr 72 000 type IV cottagenase in human colonic adenocarcinoma. Cancer Res 51:439-444, 1991.
229. [228] Boag AH, Young ID. Immunohistochemical analysis of type IV collagenase expression in prostatic adenocarcinoma and adenocarcinoma. Mod Pathol 6:65-68, 1993.
230. [229] Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson W, Liotta LA. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500-507, 1992.
231. [230] Himelstein BP, Canete-Sole R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14:246-255, 1994.
232. [231] Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-P, Chambon P et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90:1843-1847, 1993.
233. [232] Engel G, Heselmeyer K, Auer G, Bäckdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 58:830-835, 1994.
234. [233] Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53:165-169, 1993.
235. [234] Wolf C, Chenard M-P, de Grossouvre PD, Bellocq J-P, Chambon P, Basset P. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 99:870-872, 1992.
236. [235] McDonnell S, Navre M, Coffey RJ, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4:527-533, 1991.
237. [236] Marcotte PA, Kozan IM, Dorwin SA, Ryan JM. The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (Pro)urokinase in cultures of normal human kidney cells. J Biol Chem 267:13803-13806, 1992.
238. [237] Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144-150, 1991.
239. [238] Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P, Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734, 1995.
240. [239] Emonard HP, Remancle AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM. Tumor cell surface-associated binding site for the Mr 72 000 type IV collagenase. Cancer Res 52:5845-5848, 1992.
241. [240] Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61-65, 1994.
242. [241] Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331-5338, 1995.
243. [242] Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48:529-532, 1991.
244. [243] Otani Y. The collagenase activities, interstitial collagenase and type IV collagenase, in human stomach cancer: with special reference to local spreading and lymph node metastasis. Keio J Med 39:159-167, 1990.
245. [244] Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 70:2747-2753, 1992.
246. [245] Kusukawa J, Sasaguri Y, Shima I, Kameyama T, Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol 99:18-23, 1993.
247. [246] Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 195:159-165, 1981.
248. [247] Hicks NJ, Ward RV, Reynolds JJ. A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloprotease inhibitor (TIMP) by tumor cell lines. Int J Cancer 33:835-844, 1984.
249. [248] DeClerck YA, Yean T-D, Ratzin BJ, Lu HS, Langley KE. Purification and characterization of two related but distinct metalloprotease inhibitors secreted by bovine aortic endothelial cells. J Biol Chem 264:17445-17453, 1989.
250. [249] Boone TC, Johnson MJ, DeClerck YA, Langley KE. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc Natl Acad Sci USA 87:2800-2804, 1990.
251. [250] DeClerck YA, Yean T-D, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 51:2151-2157, 1991.
252. [251] Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 265:13933-13938, 1990.
253. [252] Alvarez OA, Carmichael DF, DeClerk YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82:589-595, 1990.
254. [253] Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779, 1991.
255. [254] DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A:2170-2180, 1994.
256. [255] Blasi F. Molecular mechanisms of protease-mediated tumor invasiveness. J Surg Oncol Suppl. 3:21-30, 1993.
257. [256] Vassali J-D, Baccino D, Belin D. A cellular binding site for the Mr 55000 form of the human plasminogen activator. J. Cell Biol. 107:2437-2445, 1985.
258. [257] Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107:2437-2445, 1988.
259. [258] Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 1992.
260. [259] Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Preliminary report. Cancer 62:531-533, 1988.
261. [260] Duffy MJ, Reilly D, O'Sullivan C. O'Higgins N, Fennelly JJ. Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335:108, 1990.
262. [261] Gröndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danö K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-I in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993.
263. [262] Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993.
264. [263] Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54:2527-2530, 1994.
265. [264] Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344:583-584, 1994.
266. [265] Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res 15:1167-1172, 1995.
267. [266] Pappot H, Gardsvoll H, Romer J, Pedersen AN, Grondahl-Hansen J, Pyke C, Brunner N. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 376:259-267, 1995.
268. [267] Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly J, Duffy M. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 1995.
269. [268] Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20:352-362, 1980.
270. [269] Thorpe S, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paulucci F et al. Association between high concentrations of Mr 52 000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989.
271. [270] Spyratos F, Brouillet JP, Defrenne A, Hacedne K, Rouesse J, Maudelonde T, Brunet M et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet ii:1115-1118, 1989.
272. [271] Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24:219-226, 1993.
273. [272] Fernö M, Baldetorp B, Borg Å, Brouillet JP, Olsson H, Rochefort H, Sellberg G et al. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group. Eur J Cancer 30A:2042-2048, 1994.
274. [273] Têtu B, Brisson J, Côté C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin-D expression in node-negative breast carcinoma: an immunohistochemical study. Int J Cancer 55:429-435, 1993.
275. [274] Baici A, Knopfel M, Keist R. Tumor-host interactions in the rabbit V2 carcinoma, stimulation of cathepsin B in host fibroblasts by a tumor-derived cytokine. Invasion Metastasis 8:143-158, 1988.
276. [275] Liaudet E, Garcia M, Rochefort H, Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 9:1145-1154, 1994.
277. [276] Kennedy AR. Prevention of carcinogenesis by protease inhibitors. Cancer Res 54:1999-2005, 1994.
278. [277] Brown PD. Preclinical and clinical studies on the matrix metalloproteinase inhibitor, batimastat (BB-94). Clin Exp Metastasis 12:23, 1994.
279. [278] Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263:526-529, 1994.
280. [279] Eisenbach L, Segal S, Feldman M. MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int J Cancer 32:113-120, 1983.
281. [280] Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M. The differential expression of H-2K versus H-2D antigens distinguishing low metastatic from high metastatic clones is correlated with the immunogenic properties of the tumor cells. Int J Cancer 34:567-573, 1984.
282. [281] Feldman M, Eisenbach L. Genes controlling the metastatic phenotype. Cancer Surv 7:555-572, 1988.
283. [282] Solana R, Romero J, Alonso C, Pena J. MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. Invasion Metastasis 12:210-217, 1992.
284. [283] van Duinen SG, Ruiter DJ, Bröcker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-1025, 1988.
285. [284] Zaloudik J, Moore M, Ghosh AK, Mechl Z, Rejthar A. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 41:1078-1084, 1988.
286. [285] Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675-679, 1986.
287. [286] Storkus WJ, Dawson JR. Target structures involved in natural killing (NK): characateristics, distribution, and candidate molecules. Crit Rev Immunol 10:393-416, 1991.
288. [287] Cavanaugh P, Nicolson GL. Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49:3928-3933, 1989.
289. [288] Nicolson GL, Menter DG, Herrmann J, Cavanaugh P, Jia L, Hamada J. Yun Z, et al. Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Crit Rev Oncog 5:451-471, 1994.
290. [289] Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 44:3448-3453, 1984.
291. [290] Smith K, Fennelly JA, D.E. N, Hall RR, Harris AL. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 49:5810-5815, 1989.
292. [291] Ozawa S, Ueda M, Ando N, Shimizu N, Abe A. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63:2169-2173, 1989.
293. [292] Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M. Antigenic profile of otumor progression stages in human melanocytic nevi and melanomas. Cancer Res 49:5091-5096, 1989.
294. [293] Yu D, Hamada J, Zhang H, Nicolson GL, Hung HC. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7:2263-2270, 1992.
295. [294] Gopalakrishna R, Barsky SH. Tumor promoter-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci USA 85:612-616, 1988.
296. [295] Galang CK, Der CJ, Hauser CA. Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. Oncogene 9:2913-2921, 1994.
297. [296] Stoker M, Gherardi E, Ferryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:238-242, 1987.
298. [297] Rosen EM, Knesel J, Goldberg ID, Jin L, Bhargava M, Joseph A, Zitnik R et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 57:706-714, 1994.
299. [298] Weidner K, Arakaki N, Vandekerckhove J, Weingart S, Hartman G, Rieder H, Fonatsch C et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88:7001-7005, 1991.
300. [299] Bottaro DP: Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, van de Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804, 1991.
301. [300] Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini PJ et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937-1941, 1993.
302. [301] Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54:1630-1633, 1994.
303. [302] Siletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 51:3507-3511, 1991.
304. [303] Nabi IR, Watanabe H, Raz A. Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev 11:5-20, 1992.
305. [304] Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rubben H, Raz A. Inverse correlation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120-3123, 1994.
306. [305] Nakamori S, Watanabe H, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 74:1855-1862, 1994.
307. [306] Lotan R, Amos B, Watanabe H, Raz A. Suppression of melanoma cell motility factor receptor expression by retinoic acid. Cancer Res 52:4878-4884, 1992.
308. [307] Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffman E. Identification, purification, and partial sequence analysis of Autaxin, a novel motiUty-stimulating protein. J Biol Chem 267:2524-2529, 1992.
309. [308] Liotta LA, Murata J, Clair HY, Årestad A, Stracke ML. cDNA cloning of the autocrine cell motifity factor, autotaxin (ATX). Clin Exp Metastasis 12:3-4, 1994.
310. [309] Shimonaka M, Yamaguchi Y. Purification and biological characterization of epitaxin, a fibroblast-derived motility factor for epithelial cells. J Biol Chem 269:14284-14289, 1994.
311. [310] Hu M, Pollock RE, Nakamura T, Nicolson GL. Human peri-tumoral and lung fibroblasts produce paracrine motility factors for recently established human sarcoma cell strains. Int J Cancer 62:585-592, 1995.
312. [311] Heimburger N, Paques EP, Romisch J. Coagulation and fibronolysis in cancer. Behring Inst Mitt Apr:169-182, 1992.
313. [312] Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 11:249-266, 1992.
314. [313] Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res 6:321-327, 1994.
315. [314] Bartoloni C, Guidi L, Tricerri A, Partiarca F, Pili R, Cursi F, Cancetta M et al. Latent coagulation disorders evaluated by the assay of plasma trombin-antithrombin III complexes in a large series of solid tumors. Oncology 49:426-430, 1992.
316. [315] Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasia 18:37-46, 1988.
317. [316] Medrano EE, Cafferata EGA, Larcher F. Role of thrombin in the proliferative response of T47D mammary tumor cells. Exp Cell Res 172:354-364, 1987.
318. [317] Nierodzik MLR, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52:3267-3272, 1992.
319. [318] McCulloch P, George WD. Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumor growth. Br J Cancer 59:179-183, 1989.
320. [319] Brown DC, Purushotham AD, George WD. Inhibition of pulmonary tumor seeding by antiplatelet and fibrinolytic therapy in an animal experimental model. J Surg Oncol 55:154-159, 1994.
321. [320] Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51:4549-4556, 1991.
322. [321] Zacharski LR, Costantini V, Wojtukiewcz MZ, Memoli VA, Kudryk J. Anticoagulants as cancer therapy. Semin Oncol 17:217-227, 1990.